Zum Inhalt springen
Sponsorship
Die MVF-Knowledge-HubsFrisch aus der Forschung. Täglich aktualisiert!

Suchen Sie in Hunderten nationaler und internationaler Datenbanken nach dem neuesten Studienwissen der angegebenen Themengebiete und/oder lassen Sie sich werktäglich per Newsletter informieren. Die Newsfeeds werden auf deutsch übersetzt and nach Übertragbarkeit auf das deutsche Gesundheits-/Versorgungssystem ausgewählt:

Zu den Knowledge-Hubs

Compatibility confirmed

According to DMKG, paracetamol is the first choice for pregnant women

The German Migraine and Headache Society (DMKG) has recently published a new guideline for the treatment of migraines and various headache syndromes during pregnancy and breastfeeding. The experts' recommendation: The first choice is the proven active ingredient paracetamol.

The package inserts for medications often contain the statement “contraindicated in pregnancy”. However, the background is usually rarely the experiences that have been carried out in studies or other research, but primarily the fact that the data does not provide any information about the use of the respective medication during pregnancy. Not so with paracetamol. According to the DMKG guidelines, this is “the safest analgesic substance in pregnancy”.

Paracetamol has been used to treat pain in pregnant and breastfeeding women for 40 years and the data convincingly proves the safety of the substance. Against this background, the DMKG guidelines come to the conclusion that paracetamol up to 1000 mg as a single dose (e.g. ben-u-ron®) is the drug of first choice for the treatment of migraines and other headaches in all phases of pregnancy.

The fact that paracetamol is the only over-the-counter active ingredient for the treatment of mild to moderate pain and fever, which is administered to newborns in the 75 mg dosage, is also evidence of its gentle mode of action. Instead of shooting at sparrows with cannons, there is paracetamol for every need the individual dosage that specifically alleviates the symptoms.

Do you want to leave us already?

Subscribe to our newsletter quickly. Then you can be sure that you won't miss anything.